{"nctId":"NCT01660256","briefTitle":"Confirmatory Study of OPC-12759 Ophthalmic Solution","startDateStruct":{"date":"2012-08"},"conditions":["Dry Eye"],"count":209,"armGroups":[{"label":"OPC-12759 ophthalmic solution","type":"EXPERIMENTAL","interventionNames":["Drug: OPC-12759"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"OPC-12759 ophthalmic suspension","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: OPC-12759"]}],"interventions":[{"name":"OPC-12759","otherNames":["rebamipide"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Out patient\n2. Subjective complaint of dry eye that has been present for minimum 20 months\n3. Ocular discomfort severity is moderate to severe\n4. Corneal - conjunctival damage is moderate to severe\n5. Unanesthetized Schirmer's test score of 5mm/5minutes or less\n6. Best corrected visual acuity of 0.2 or better in both eyes\n\nExclusion Criteria:\n\n1. Presence of anterior segment disease or disorder other than that associated with dry eye\n2. Ocular hypertension patient or glaucoma patient with ophthalmic solution\n3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study\n4. Anticipated use of contact lens during the study\n5. Patient with punctal plug\n6. Any history of ocular surgery within 12 months\n7. Female patients who are pregnant,possibly pregnant or breast feeding\n8. Known hypersensitivity to any component of the study drug or procedural medications\n9. Receipt of any investigational product within 4 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Fluorescein Corneal Staining (FCS) Score From Baseline","description":"FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better.\n\nChanges of the FCS score from baseline to the last dose (last observation carried forward \\[LOCF\\]) were compared between 2% OPC-12759 ophthalmic solution and placebo by the t-test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"0.2"},{"groupId":"OG001","value":"-2.0","spread":"0.3"},{"groupId":"OG002","value":"-2.9","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline","description":"LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctiva was divided into 6 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-18). 0 is better.\n\nThe scores and change from baseline at each examination (including LOCF) were compared between 2% OPC-12759 ophthalmic solution and placebo ophthalmic solution.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"0.3"},{"groupId":"OG001","value":"-1.7","spread":"0.3"},{"groupId":"OG002","value":"-3.1","spread":"0.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":84},"commonTop":["Dysgeusia","Nasopharyngitis","Abnormal sensation in eye","Eye irritation","Ocular discomfort"]}}}